Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xisomab 3G3 in healthy adults
NCT03097341Phase 1Completed
- Sponsor
- Aronora, Inc.
- Start
- Jun 2017
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Xisomab 3G3 in thrombosis (5 arms), sponsored by Aronora, Inc. Primary endpoints: Treatment-related Adverse Events, Abnormal Vital Signs and 4 more. Started Jun 2017; status: completed.
02
Drugs
Xisomab 3G3
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03097341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097341.